CN109952307A - 4’-硫代-2’-氟代核苷磷酰胺化合物的固体形式及其制备方法和用途 - Google Patents

4’-硫代-2’-氟代核苷磷酰胺化合物的固体形式及其制备方法和用途 Download PDF

Info

Publication number
CN109952307A
CN109952307A CN201780065200.7A CN201780065200A CN109952307A CN 109952307 A CN109952307 A CN 109952307A CN 201780065200 A CN201780065200 A CN 201780065200A CN 109952307 A CN109952307 A CN 109952307A
Authority
CN
China
Prior art keywords
crystal
compound
formula
diffraction
angle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780065200.7A
Other languages
English (en)
Other versions
CN109952307B (zh
Inventor
杨成喜
梁玉峰
周江峰
葛建华
田强
赵明亮
曾宏
赵富录
韩剑锋
王利春
王晶翼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Original Assignee
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Publication of CN109952307A publication Critical patent/CN109952307A/zh
Application granted granted Critical
Publication of CN109952307B publication Critical patent/CN109952307B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN201780065200.7A 2016-12-22 2017-12-15 4’-硫代-2’-氟代核苷磷酰胺化合物的固体形式及其制备方法和用途 Active CN109952307B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201611199468 2016-12-22
CN2016111994683 2016-12-22
PCT/CN2017/116396 WO2018113592A1 (zh) 2016-12-22 2017-12-15 4'-硫代-2'-氟代核苷磷酰胺化合物的固体形式及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN109952307A true CN109952307A (zh) 2019-06-28
CN109952307B CN109952307B (zh) 2022-03-25

Family

ID=62624717

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780065200.7A Active CN109952307B (zh) 2016-12-22 2017-12-15 4’-硫代-2’-氟代核苷磷酰胺化合物的固体形式及其制备方法和用途

Country Status (8)

Country Link
US (1) US10787477B2 (zh)
EP (1) EP3560944A4 (zh)
JP (1) JP2020502043A (zh)
CN (1) CN109952307B (zh)
AU (1) AU2017383598B2 (zh)
CA (1) CA3041420A1 (zh)
EA (1) EA201990780A1 (zh)
WO (1) WO2018113592A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015220313A (ja) 2014-05-16 2015-12-07 ソニー株式会社 固体撮像装置およびその製造方法、並びに電子機器
CA3138234A1 (en) * 2019-04-30 2020-11-05 Beijing Tide Pharmaceutical Co., Ltd. Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104321333A (zh) * 2012-03-21 2015-01-28 沃泰克斯药物股份有限公司 硫代氨基磷酸酯核苷酸前药的固体形式
WO2016068341A1 (ja) * 2014-10-31 2016-05-06 富士フイルム株式会社 チオヌクレオシド誘導体またはその塩および医薬組成物
CN105873593A (zh) * 2013-12-23 2016-08-17 吉利德制药有限责任公司 抗病毒索非布韦类似物的晶型
WO2016155593A1 (zh) * 2015-04-03 2016-10-06 四川科伦药物研究院有限公司 4'-硫代核苷的新型化合物及其制备方法、药物组合物和应用
WO2016189055A1 (en) * 2015-05-27 2016-12-01 Idenix Pharmaceuticals Llc Nucleotides for the treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128458A (en) 1990-04-20 1992-07-07 Southern Research Institute 2',3'-dideoxy-4'-thioribonucleosides as antiviral agents
ES2182061T3 (es) 1996-04-09 2003-03-01 Yamasa Corp 1 - (2 - desoxi - 2 - fluor-4- tio-beta-d arabinofuranosil)citosina.
EP3004130B1 (en) * 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucleosides for the treatment of hcv

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104321333A (zh) * 2012-03-21 2015-01-28 沃泰克斯药物股份有限公司 硫代氨基磷酸酯核苷酸前药的固体形式
CN105873593A (zh) * 2013-12-23 2016-08-17 吉利德制药有限责任公司 抗病毒索非布韦类似物的晶型
WO2016068341A1 (ja) * 2014-10-31 2016-05-06 富士フイルム株式会社 チオヌクレオシド誘導体またはその塩および医薬組成物
WO2016155593A1 (zh) * 2015-04-03 2016-10-06 四川科伦药物研究院有限公司 4'-硫代核苷的新型化合物及其制备方法、药物组合物和应用
WO2016189055A1 (en) * 2015-05-27 2016-12-01 Idenix Pharmaceuticals Llc Nucleotides for the treatment of cancer

Also Published As

Publication number Publication date
CN109952307B (zh) 2022-03-25
US10787477B2 (en) 2020-09-29
EA201990780A1 (ru) 2019-11-29
AU2017383598A1 (en) 2019-05-16
WO2018113592A1 (zh) 2018-06-28
EP3560944A4 (en) 2020-08-26
CA3041420A1 (en) 2018-06-28
US20190241603A1 (en) 2019-08-08
EP3560944A1 (en) 2019-10-30
JP2020502043A (ja) 2020-01-23
AU2017383598B2 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
US8884013B2 (en) Polymorphs of Dasatinib, preparation methods and pharmaceutical compositions thereof
RU2414470C2 (ru) Кристаллические формы соединения тиазолидиндиона и способ его получения
CN105153122B (zh) [(吲哚-3-基)嘧啶-2-基]氨基苯基丙-2-烯酰胺衍生物及盐、制备方法、应用
CN109311832B (zh) 沃替西汀的帕莫酸盐及其晶型
US20060160785A1 (en) Ezetimibe polymorphs
CA2584365A1 (en) Ascomycin crystalline forms and preparation thereof
US11053224B2 (en) Polymorphic forms of kinase inhibitor compound, pharmaceutical composition containing same, preparation method therefor and use thereof
US7759481B2 (en) Solid state forms of 5-azacytidine and processes for preparation thereof
CA2573781A1 (en) Processes for preparation of crystalline mycophenolate sodium
CN112142679A (zh) 一种吉非替尼与香草酸共晶甲醇溶剂合物及其制备方法
US10323035B2 (en) Co-crystal of a CDK inhibitor and an MEK inhibitor and process of preparation thereof
CN106554347A (zh) Egfr激酶抑制剂及其制备方法和应用
CN109952307A (zh) 4’-硫代-2’-氟代核苷磷酰胺化合物的固体形式及其制备方法和用途
PT1507531E (pt) Composições farmacêuticas estáveis de desloratadina
CN103936726A (zh) 晶体、制备方法及其用途
KR20080022595A (ko) 지프라시돈 ＨＣｌ의 다형 형태 및 그 제조 방법
WO2023193563A1 (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
CN110325536A (zh) Janus激酶抑制剂的晶体形式
CN113966332A (zh) Cdk9抑制剂的多晶型物及其制法和用途
CN108570045B (zh) 氢溴酸山莨菪碱的晶型、其制备方法、药物组合物
CA2990747C (en) Phenyl amino pyrimidine compound or polymorph of salt thereof
WO2019149090A1 (zh) 一种尿酸转运体1抑制剂的晶体及其制备方法和用途
CN105753869B (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
CN105367492B (zh) 他喹莫德的晶型及其制备方法、其药物组合物和用途
WO2021143819A1 (zh) 多环类间变性淋巴瘤激酶抑制剂的晶型

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40004865

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant